{"id":84,"date":"2013-02-04T16:38:57","date_gmt":"2013-02-04T21:38:57","guid":{"rendered":"http:\/\/licensinglaw.net\/blog3\/?page_id=84"},"modified":"2021-04-09T11:56:04","modified_gmt":"2021-04-09T15:56:04","slug":"difficult-cases","status":"publish","type":"page","link":"https:\/\/licensinglaw.net\/blog3\/?page_id=84","title":{"rendered":"Difficult Cases"},"content":{"rendered":"<p style=\"text-align: justify;\">An unusually-productive relationship between University College London Medical School, Ark Therapeutics Ltd. (ticker LSE: AKT.L) and Boehringer-Ingleheim GmbH produced evidence that certain anti-hypertensive medicines, including Boehringer-Ingleheim\u2019s Mycardis\u00ae telmisartan, prevent stroke and heart attack.\u00a0 Patenting either of these two new indications could provide important commercial protection for Mycardis\u00ae.<\/p>\n<p style=\"text-align: justify;\">The U.S. Patent Office, however, thought that using an anti-hypertensive medicine like telmisartan to prevent stroke or heart attack was obvious.\u00a0 Thus, over a decade after filing the priority application, the applicant was still without a patent on heart attack or stroke.\u00a0 With only two years of Mycardis\u00ae data exclusivity remaining, the situation became urgent.<\/p>\n<figure id=\"attachment_266\" aria-describedby=\"caption-attachment-266\" style=\"width: 300px\" class=\"wp-caption alignright\"><a href=\"http:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/2013\/02\/AKT.L-Stock-price.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-266 size-medium\" src=\"https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/2013\/02\/AKT.L-Stock-price-300x231.jpg\" alt=\"A patent award makes for a happy July 4th.  \" width=\"300\" height=\"231\" srcset=\"https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/2013\/02\/AKT.L-Stock-price-300x231.jpg 300w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/2013\/02\/AKT.L-Stock-price-1024x790.jpg 1024w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/2013\/02\/AKT.L-Stock-price-250x193.jpg 250w, https:\/\/licensinglaw.net\/blog3\/wp-content\/uploads\/2013\/02\/AKT.L-Stock-price-700x540.jpg 700w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><figcaption id=\"caption-attachment-266\" class=\"wp-caption-text\">A patent award makes for a happy July 4th.<\/figcaption><\/figure>\n<p style=\"text-align: justify;\">We were brought in to see if we could help.\u00a0 Just before data exclusivity expired, we won patents claiming the use of telmisartan to protect against both myocardial infarction (<a href=\"https:\/\/licensinglaw.net\/blog3\/?page_id=772\">US07998953<\/a>) and stroke (<a href=\"https:\/\/licensinglaw.net\/blog3\/?page_id=777\">US08003679<\/a>).\u00a0 On news of the patent grants (July 4th), Ark Therapeutics&#8217; stock price tripled in value.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>An unusually-productive relationship between University College London Medical School, Ark Therapeutics Ltd. (ticker LSE: AKT.L) and Boehringer-Ingleheim GmbH produced evidence that certain anti-hypertensive medicines, including Boehringer-Ingleheim\u2019s Mycardis\u00ae telmisartan, prevent stroke and heart attack.\u00a0 Patenting either of these two new indications could provide important commercial protection for Mycardis\u00ae. The U.S. Patent &#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":9,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"template-full-width.php","meta":{"footnotes":""},"class_list":["post-84","page","type-page","status-publish","hentry","column","twocol"],"_links":{"self":[{"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages\/84","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=84"}],"version-history":[{"count":14,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages\/84\/revisions"}],"predecessor-version":[{"id":780,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages\/84\/revisions\/780"}],"up":[{"embeddable":true,"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=\/wp\/v2\/pages\/9"}],"wp:attachment":[{"href":"https:\/\/licensinglaw.net\/blog3\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=84"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}